Lateral Flow Assays (LFAs) are a widely used diagnostic test format - COVID rapid antigen tests and home pregnancy hormone tests, for example. Unfortunately, traditional LFAs are not sensitive enough for many applications and only provide a positive or negative result.
At Afimacheck, we are developing a robust technology for reading lateral flow assays that greatly improves the level-of-detection. Our reader is capable of working with most commercial LFAs to enhance results and open the door to new testing opportunities.
Proven 10x level of detection improvement for commercially available lateral flow assays. Capable of measuring THC in oral fluids at 2ng/ml with 96% accuracy.
Patented technology delivers digital results less than a minute - no need for imprecise and error-prone visual interpretation.
Platform technology enhances the capabilities of any lateral flow assay using gold nanopartcles or latex color beads.
The AfimaCheck Reader empowers workplace drug testing enabling zero-tolerance cannabis policies. Our technology is able to detect and quantify the presence of cannabis in oral fluid at concentrations as low as 2ng/ml.
Our patented thermophotonic lock-in technology allows quantitative measurements of existing Lateral Flow Assays. We are unlocking unprecedented detection sensitivity in low-cost paper-based testing.
ON-SITE ORAL FLUID TESTING FOR CANNABIS USE
DETECTION OF SARS-COVID2 WITHIN 6 DAYS OF INFECTION
HERD HEALTH MONITORING AND AFLATOXIN DETECTION
POINT-OF-NEED DEVICES FOR FOOD-BORNE PATHOGEN AND ALLERGEN SCREENING.
SCREENING FOR DISEASE MARKERS AND BLOOD ANTIGEN LEVELS.
RAPID TESTING FOR THC IN ORAL FLUIDS AT THE LEGAL LIMITS